Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis

Arthritis Care and Research

Volumn 65, Issue 2, 2013, Pages 281-287

  Kollert, Florian ^a   Christoph, Sophie ^a   Probst, Corina ^a   Budweiser, Stephan ^b   Bannert, Bettina ^a   Binder, Moritz ^a   Sehnert, Bettina ^a   Voll, Reinhard E ^a   Warnatz, Klaus ^a   Zissel, Gernot ^a   Walker, Ulrich A ^c   Prasse, Antje ^a   Saalbach, Anja ^d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b RoMed Clinical Center Rosenheim   (Germany)

^c Felix Platter Spital   (Switzerland)

^d UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CARBON MONOXIDE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; SOLUBLE CD90 ANTIGEN; THY 1 ANTIGEN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

AREA UNDER THE CURVE; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; ECHOCARDIOGRAPHY; HUMAN; LUNG ARTERY PRESSURE; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG FUNCTION; LUNG LAVAGE; MAJOR CLINICAL STUDY; PULMONARY HYPERTENSION; RECEIVER OPERATING CHARACTERISTIC; RETROPERITONEAL FIBROSIS; SENSITIVITY AND SPECIFICITY; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; WALKING;

ANTIGENS, THY-1; AREA UNDER CURVE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; E-SELECTIN; FEMALE; HUMANS; LOGISTIC MODELS; LUNG DISEASES; MALE; ROC CURVE; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84873101089     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21799     Document Type: Article

References (37)

1. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15.
2. Lambova S, Muller-Ladner U,. Connective tissue diseases: treatment of digital ulcers in systemic sclerosis. Nat Rev Rheumatol 2011; 7: 5-6.
3. Abraham DJ, Krieg T, Distler J, Distler O,. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009; 48 Suppl: iii3-7.
4. Usategui A, Del Rey MJ, Pablos JL,. Fibroblast abnormalities in the pathogenesis of systemic sclerosis. Expert Rev Clin Immunol 2011; 7: 491-8.
5. Prasse A, Pechkovsky DV, Toews GB, Schafer M, Eggeling S, Ludwig C, et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 2007; 56: 1685-93.
6. Pechkovsky DV, Prasse A, Kollert F, Engel KM, Dentler J, Luttmann W, et al. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. Clin Immunol 2010; 137: 89-101.
7. Dalchau R, Daar AS, Fabre JW,. The human Thy-1 molecule. Immunol Ser 1989; 45: 185-96.
8. Williams AF, Gagnon J,. Neuronal cell Thy-1 glycoprotein: homology with immunoglobulin. Science 1982; 216: 696-703.
9. Saalbach A, Haustein UF, Anderegg U,. A ligand of human thy-1 is localized on polymorphonuclear leukocytes and monocytes and mediates the binding to activated thy-1-positive microvascular endothelial cells and fibroblasts. J Invest Dermatol 2000; 115: 882-8.
10. Saalbach A, Hildebrandt G, Haustein UF, Anderegg U,. The Thy-1/Thy-1 ligand interaction is involved in binding of melanoma cells to activated Thy-1-positive microvascular endothelial cells. Microvasc Res 2002; 64: 86-93.
11. Wetzel A, Chavakis T, Preissner KT, Sticherling M, Haustein UF, Anderegg U, et al. Human Thy-1 (CD90) on activated endothelial cells is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Immunol 2004; 172: 3850-9.
12. Denton CP, Bickerstaff MC, Shiwen X, Carulli MT, Haskard DO, Dubois RM, et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995; 34: 1048-54.
13. Shahin AA, Anwar S, Elawar AH, Sharaf AE, Hamid MA, Eleinin AA, et al. Circulating soluble adhesion molecules in patients with systemic sclerosis: correlation between circulating soluble vascular cell adhesion molecule-1 (sVCAM-1) and impaired left ventricular diastolic function. Rheumatol Int 2000; 20: 21-4.
14. Hagood JS, Prabhakaran P, Kumbla P, Salazar L, MacEwen MW, Barker TH, et al. Loss of fibroblast Thy-1 expression correlates with lung fibrogenesis. Am J Pathol 2005; 167: 365-79.
15. Saalbach A, Wetzig T, Haustein UF, Anderegg U,. Detection of human soluble Thy-1 in serum by ELISA: fibroblasts and activated endothelial cells are a possible source of soluble Thy-1 in serum. Cell Tissue Res 1999; 298: 307-15.
16. Vaglio A, Pipitone N, Salvarani C,. Chronic periaortitis: a large-vessel vasculitis? Curr Opin Rheumatol 2011; 23: 1-6.
17. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
18. Vaglio A, Salvarani C, Buzio C,. Retroperitoneal fibrosis. Lancet 2006; 367: 241-51.
19. Clements PJ, Lachenbruch PA, Ng SC, Simmons M, Sterz M, Furst DE,. Skin score: a semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 1990; 33: 1256-63.
20. Rodnan GP, Lipinski E, Luksick J,. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979; 22: 130-40.
21. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor): recommendations for a standard technique. 1995 update. Am J Respir Crit Care Med 1995; 152: 2185-98.
22. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-36.
23. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-7.
24. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2007; 66: 754-63.
25. Negi VS, Tripathy NK, Misra R, Nityanand S,. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 1998; 25: 462-6.
26. Arends SJ, Damoiseaux J, Duijvestijn A, Debrus-Palmans L, Boomars K, Broers B, et al. Prevalence of anti-endothelial cell antibodies in idiopathic pulmonary arterial hypertension. Eur Respir J 2010; 35: 923-5.
27. Kherbeck N, Tamby MC, Bussone G, Dib H, Perros F, Humbert M, et al. The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. Clin Rev Allergy Immunol 2011. E-pub ahead of print.
28. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis: their role in early and late disease. Pathobiology 1993; 61: 239-46.
29. Schubert K, Polte T, Bonisch U, Schader S, Holtappels R, Hildebrandt G, et al. Thy-1 (CD90) regulates the extravasation of leukocytes during inflammation. Eur J Immunol 2011; 41: 645-56.
30. Saalbach A, Aust G, Haustein UF, Herrmann K, Anderegg U,. The fibroblast-specific MAb AS02: a novel tool for detection and elimination of human fibroblasts. Cell Tissue Res 1997; 290: 593-9.
31. Vitetta ES, Uhr JW, Boyse EA,. Metabolism of H-2 and Thy-1 (θ) alloantigens in murine thymocytes. Eur J Immunol 1974; 4: 276-82.
32. Leeuwenberg JF, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Jeunhomme TM, et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992; 77: 543-9.
33. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S,. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol 2005; 24: 111-6.
34. Iannone F, Riccardi MT, Guiducci S, Bizzoca R, Cinelli M, Matucci-Cerinic M, et al. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis 2008; 67: 1121-6.
35. McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V,. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford) 2009; 48 Suppl: iii25-31.
36. Sanders YY, Pardo A, Selman M, Nuovo GJ, Tollefsbol TO, Siegal GP, et al. Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am J Respir Cell Mol Biol 2008; 39: 610-8.
37. Ramirez G, Hagood JS, Sanders Y, Ramirez R, Becerril C, Segura L, et al. Absence of Thy-1 results in TGF-β induced MMP-9 expression and confers a profibrotic phenotype to human lung fibroblasts. Lab Invest 2011; 91: 1206-18.